MeTC7 is a small molecule antagonist of the vitamin D receptor (VDR) that demonstrates antitumor properties by suppressing PD-L1. It has shown efficacy in inhibiting tumor growth in both xenograft and transgenic mouse models, making it a valuable tool for cancer immunotherapy and oncology research.